Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC7001A is an investigational oral small-molecule drug formulated as a capsule for the treatment of autoimmune diseases, specifically systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Originally developed by Heronova Pharmaceuticals, the asset is currently being developed by Beijing Double-Crane Runchuang Technology, a wholly-owned subsidiary of China Resources Double-Crane Pharmaceutical. DC7001A has received clinical trial approvals (IND clearance) from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), establishing a dual-jurisdiction clinical development pathway. The exact molecular target and mechanism of action of DC7001A have not been publicly disclosed by the developers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DC7001A.